iifl-logo

Glenmark Pharmaceuticals Ltd Historical Data

Add as a Preferred Source on Google
2,173.8
(1.37%)
Jun 12, 2026|05:30:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

Glenmark Pharmaceuticals Ltd Historical Data

13/05/2026calendar-icon
13/06/2026calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

13-May-2026

2,245.2

2,326.52,245.22,277.639,6502,32,68,30,237.95,48,882

14-May-2026

2,300

2,350.42,292.62,340.642,7762,25,26,13,917.34,78,398

15-May-2026

2,345.9

2,367.92,317.12,325.923,23460,13,75,114.11,01,498

18-May-2026

2,329.7

2,353.32,3012,339.928,3671,00,05,55,074.42,00,838

19-May-2026

2,351.5

2,413.52,3352,405.945,1362,04,33,72,168.34,54,611

20-May-2026

2,410.2

2,4272,3702,37960,5732,32,94,62,061.34,54,328

21-May-2026

2,395

2,407.82,3722,39324,00891,34,79,183.81,50,723

22-May-2026

2,390

2,413.92,226.32,259.165,7203,64,16,03,356.54,55,723

25-May-2026

2,268.1

2,363.42,268.12,33740,5951,89,15,04,487.61,84,807

26-May-2026

2,318

2,3732,317.92,351.430,3531,12,84,67,470.22,16,517

27-May-2026

2,322

2,3902,3222,384.928,4191,28,13,73,3992,38,355

29-May-2026

2,400

2,400.72,257.82,274.960,5573,11,60,44,391.16,71,001

01-Jun-2026

2,288.8

2,3002,179.82,201.21,03,6244,47,73,51,473.63,89,500

02-Jun-2026

2,218.7

2,236.82,144.32,184.653,9062,64,70,59,407.66,35,243

03-Jun-2026

2,193.9

2,2222,148.22,17465,7162,36,46,61,2705,89,064

04-Jun-2026

2,174

2,207.92,146.52,180.640,5911,24,66,73,4093,04,870

05-Jun-2026

2,191.9

2,216.22,1612,166.230,6601,11,84,61,411.52,54,017

08-Jun-2026

2,148

2,207.42,132.22,176.533,8821,07,30,43,788.41,72,652

09-Jun-2026

2,176.5

2,2212,164.12,209.635,0381,23,70,60,994.32,43,865

10-Jun-2026

2,232

2,252.52,137.12,144.441,1652,47,82,97,326.53,49,638

11-Jun-2026

2,144.6

2,170.32,140.42,144.521,12376,12,93,747.61,42,718

12-Jun-2026

2,171.8

2,1782,1172,173.829,8951,07,87,17,601.42,10,255

Glenmark Pharma.: Related NEWS

Glenmark Pharma Q3 FY26 Profit Rises 16% to ₹403.2 Crore

Revenue from North America increased 24% year on year to ₹970.6 crore, including income from the out licensing of ISB 2001.

31 Jan 2026|02:22 PM
Read More
Top Stocks for Today - 25th September 2025

Here are some of the stocks that may see significant price movement today: Polycab India, Tata Steel, Dalmia Bharat, etc.

25 Sep 2025|06:57 AM
Read More
Top Stocks for Today - 23rd September 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Rail Vikas Nigam, Birla Corp, etc.

23 Sep 2025|07:01 AM
Read More
Glenmark subsidiary gets $700 Million in licensing deal; stock gains

At around 2.19 PM, Glenmark Pharma was trading 2.97% higher at ₹2,112.90 per piece, against the previous close of ₹2,051.90 on NSE.

9 Sep 2025|02:31 PM
Read More
Glenmark Pharma Q1 Net Profit Falls 86% YoY to ₹47 Crore

Operating performance was slightly weaker, with EBITDA dipping 1.4% to ₹580 crore from ₹588.2 crore.

18 Aug 2025|01:03 PM
Read More
Top Stocks for Today - 18th August 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharmaceuticals, Vedanta, Inox Wind, etc.

18 Aug 2025|08:14 AM
Read More
Glenmark Shares Surge 10% After AbbVie Inks Licensing Deal for ISB 2001

The compound is currently in Phase 1B clinical trials, being studied for multiple myeloma, a tough-to-treat form of blood cancer.

11 Jul 2025|09:48 AM
Read More
Top Stocks for Today - 11th July 2025

Here are some of the stocks that may see significant price movement today: Tata Consultancy Services, IREDA, Glenmark Pharma, etc.

11 Jul 2025|07:20 AM
Read More
Top Stocks for Today - 26th May 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.

26 May 2025|06:34 AM
Read More
Glenmark Pharma’s cancer drug receive FDA ‘fast track’ status

ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.

6 May 2025|09:31 AM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.